Background-In general, Ras proteins are thought to promote cardiac hypertrophy, an important risk factor for cardiovascular disease and heart failure. However, the contribution of different Ras isoforms has not been investigated. The objective of this study was to define the role of H-and K-Ras in modulating stress-induced myocardial hypertrophy and failure. Methods and Results-We used H-and K-Ras gene knockout mice and subjected them to pressure overload to induce cardiac hypertrophy and dysfunction. We observed a worsened cardiac phenotype in Hras −/− mice, while outcomes were improved in Kras +/− mice. We also used a neonatal rat cardiomyocyte culture system to elucidate the mechanisms underlying these observations. Our findings demonstrate that H-Ras, but not K-Ras, promotes cardiomyocyte hypertrophy both in vivo and in vitro. This response was mediated in part through the phosphoinositide 3-kinase-AKT signaling pathway. Adenoassociated virus-mediated increase in AKT activation improved the cardiac function in pressure overloaded Hras null hearts in vivo. These findings further support engagement of the phosphoinositide 3-kinase-AKT signaling axis by H-Ras. Conclusions-Taken together, these findings indicate that H-and K-Ras have divergent effects on cardiac hypertrophy and heart failure in response to pressure overload stress. (Circ Heart Fail. 2017;10:e003658.
T he Ras family of small GTPases consists of ubiquitously expressed signal transducers that relay extracellular cues inside the cell, thereby, regulating a host of signaling pathways and cellular responses. 1 Activation of Ras proteins is modulated through engagement of transmembrane receptors, both receptor tyrosine kinases and G-protein-coupled receptors, and through mechanical forces, that is, cell stretch/strain. These signals lead to guanine nucleotide exchange factor activation and Ras GTP loading. GTP-bound Ras is active and is able to bind to and signal through downstream effectors, the most established being Raf, 2-5 phosphoinositide 3-kinase (PI3K), 6 RalGDS, [7] [8] [9] PLCε, 10 and Tiam1. 11 Signal pathways elicited via Ras can modulate a variety of responses, including gene expression, growth, survival, proliferation, endocytosis, and cell motility.
See Clinical Perspective
Ras proteins are highly relevant to human disease, and myriad studies have demonstrated Ras mutations in many types of cancers. 12 Human germ line mutations in Ras proteins, and known modulators of Ras signaling pathways, have been linked to the developmental disorders Neurofibromatosis type 1, cardio-facio-cutaneous, 13, 14 Noonan, [15] [16] [17] Costello, 18 and LEOPARD syndromes. Collectively referred to as RASopathies, these genetic disorders share dysregulation of Ras/mitogen-activated protein kinase (MAPK) signaling and phenotypic overlap, including craniofacial abnormalities, cardiac malformations, impaired cognitive ability, and increased cancer risk. Specifically, these patients present with cardiovascular abnormalities, including hypertrophic cardiomyopathy, atrial-septal defects, pulmonic stenosis, and tachycardia. Although the nature of these cardiac defects is heterogeneous and the cause of these differences remains unclear, these syndromes provide strong evidence of the importance of Ras proteins in human myocardial pathophysiology.
To date, studies investigating the role of Ras signaling in a cardiac context have almost exclusively focused on the H-Ras isoform. Early work demonstrated that agonists and interventions that promote cardiomyocyte hypertrophy, characterized by increased cell size and activation of embryonic gene expression, also elicit activation of Ras. 19, 20 This growth response was demonstrated to require Ras activity, and later, the expression of activated H-Ras was shown to be sufficient to promote cardiomyocyte hypertrophy. 19, 21, 22 Myocardial expression of activated H-Ras12V driven by the myosin light chain 2v promoter was shown to cause increased left ventricular (LV) mass, hypertrophic gene expression, and functional decompensation H-Ras Mediates Cardioprotection via AKT in transgenic animals, 23 further supporting the hypothesis that H-Ras promotes cardiomyocyte hypertrophy, as well as suggesting a maladaptive response to increased cardiac H-Ras activity. Additional studies suggested that this response was reversible and may involve altered sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) function and calcium handling. 24 The objective of the current study was to determine the role of endogenous H-and K-Ras in pressure overloadinduced cardiac hypertrophy and heart failure. We used genetic loss-of-function mouse models and cultured neonatal rat cardiomyocytes (NRCMs) to interrogate each isoform in vivo and in vitro. Our findings indicate that H-Ras promotes cardiomyocyte hypertrophy and is cardioprotective during chronic pressure overload, whereas K-Ras does not promote growth and serves a deleterious function. We observed markedly less phosphorylated AKT and extracellular signal-regulated kinase (ERK) in pressure-overloaded Hras null hearts. Inhibition of AKT activation attenuated H-Ras-induced cardiomyocyte hypertrophy in vitro, and restoration of AKT signaling in vivo was able to rescue cardiac function in pressure-overloaded Hras null hearts. These results suggest that endogenous H-Ras mediates hemodynamic stress-induced cardiac hypertrophy and affords a cardioprotective function in the murine heart in part through activation of AKT.
Methods
An expanded Methods section is available in the Data Supplement.
Animals

Kras
+/− and Hras +/− mice have been described previously. 25, 26 All protocols concerning the use of animals were approved by the Institutional Animal Care and Use Committee at Rutgers, New Jersey Medical School.
Transverse Aortic Constriction
Mice were anesthetized and pressure overload induced by ligation of the transverse thoracic aorta. Sham operation was performed without aortic constriction.
Histology
Hearts were analyzed for interstitial fibrosis using Masson's Trichrome, myocyte cross-sectional area (CSA) using wheat germ agglutinin, and apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).
RBD Pull-Down Assay
Homogenates were incubated with Raf-1 RBD agarose (Upstate, Millipore) for 40 minutes at 4°C to precipitate GTP-bound Ras according to manufacturer's instructions.
Statistical Analysis
All data are reported as mean±standard error of the mean. Student's t test was used to evaluate the difference in means between 2 groups. Multiple groups were analyzed using Levene's test to determine heterogeneity of variances, followed by Welch's analysis of variance. Post hoc multiple comparisons were performed using Tukey's test. Statistical analyses were performed using SPSS v24 and Graph Pad Prism 6.0. A P value <0.05 was considered significant.
Results
To determine the role of endogenous Ras isoforms on basal cardiac structure and function, we used H-and K-Ras loss-of-function mouse lines. Homozygous deletion of Kras is embryonic lethal 25 ; therefore, we used Kras +/− mice for this study. Kras +/− mice are viable and showed no obvious cardiac abnormalities in heart size, structure, and function compared with WT controls at baseline (10-12 weeks; Figure 1A through 1D) . Interestingly, homozygous disruption of Hras is tolerated, and mice are born at expected Mendelian ratios. 26 However, by 10 to 12 weeks of age, Hras −/− mice developed a mild but significant reduction in cardiac function, as determined by echocardiographic analysis (percent LV ejection fraction [%LVEF]; Figure 1E through 1H) . Hras −/− mice also had a modest but significant reduction in LV mass when compared with WT controls. In contrast, Hras +/− mice showed no difference in cardiac size or function compared with WT mice at baseline ( Figure 1E through 1H) .
Mechanical stretch is known to activate Ras proteins in cardiomyocytes. 20 We, therefore, subjected WT mice to 1 and 7 days of pressure overload by transverse aortic constriction (TAC) and determined H-and K-Ras activation in the myocardium. We found that both isoforms were activated at 1 day post-TAC; however, only K-Ras activation was increased at 7 days post-TAC (Figure 2A and 2B) . To determine the role of these Ras isoforms in mediating pressure overload-induced cardiac hypertrophy and dysfunction, H-and K-Ras mutant mice were subjected to 4-week TAC. There was no significant difference in pressure gradients achieved in all TAC experiments ( Figure I in the Data Supplement). In response to pressure overload, Kras +/− mice showed a similar increase in cardiac hypertrophy, as determined by LV weight/tibia length, cardiomyocyte CSA, and fetal gene expression, when compared with WT littermates (Figure 2C through 2E; Figure II in the Data Supplement). However, we observed a trend toward reduced myocardial fibrosis and a significant reduction in TUNEL-positive cells in Kras +/− hearts after TAC compared with those of WT mice ( Figure 2F through 2H). Importantly, %LVEF was significantly greater in Kras +/− mice compared with that in WT mice after 4 weeks of TAC ( Figure 2I and Table 1 ). Furthermore, in Kras +/− mice, LV end-diastolic dimension was significantly smaller compared with that in WT controls after TAC (Table 1) , indicating attenuated chamber dilatation and improved systolic function. Taken together, these results indicate that reduced K-Ras expression does not alter the hypertrophic capability of the mouse heart but does attenuate cardiac maladaptation to pressure overload stress.
H-Ras mutant mice were also subjected to pressure overload and assessed. Pressure overload-induced increases in LV weight/tibia length and cardiomyocyte CSA were not significantly different between Hras +/− mice and WT controls. However, Hras −/− mice had significantly attenuated LV weight/ 
through 3F). Cardiac function (%LVEF) in Hras
+/− mice declined to a similar extent as in WT mice after 4 weeks of TAC. However, %LVEF was significantly further reduced in the Hras −/− mice after pressure overload ( Figure 3G and Table 2 ). Moreover, septal wall thickness was significantly smaller in Hras +/− and Hras −/− mice after TAC compared with that in WT mice. These results suggest that H-Ras may contribute to the hypertrophic process in response to pressure overload stress.
To further investigate the underlying mechanism, we used the culture of NRCMs. We ectopically expressed activated Hand K-Ras12V in cultured cardiomyocytes using adenoviral gene transfer. We found that expression of activated H-Ras12V elicited a significant increase in cell surface area as well as protein:DNA content compared with that in LacZ control. In contrast, K-Ras12V expression did not alter cell surface area or protein:DNA content compared with that in LacZ control, suggesting that H-Ras selectively promotes cardiomyocyte hypertrophy in a cell autonomous manner ( Figure 4A through 4C). We further evaluated hypertrophy by measuring fetal gene induction. By quantitative reverse transcriptase polymerase chain reaction analysis, we determined that H-Ras expression induced significant increases in ANF, BNP, and β-MHC mRNA expression, whereas K-Ras expression did not significantly alter atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), or β-myosin heavy chain (MHC) expression, compared with those in LacZ control-infected NRCMs ( Figure 4D through 4F). These results are in agreement with our previous findings that showed differential signaling elicited by H-and K-Ras in cardiomyocytes 27 and demonstrate that H-Ras activation is sufficient to induce a hypertrophic response in NRCMs. We speculate that differences in isoform signaling may be because of differences in subcellular localization, which were observed by fractionation of ventricular tissue ( Figure III in the Data Supplement). Importantly, a complimentary approach using RNAi-mediated depletion of endogenous H-Ras completely abolished the phenylephrine-induced expression of the hypertrophic markers ANF and BNP, indicating that H-Ras Our recent work demonstrated that activation of K-Ras by oxidative stress in cardiomyocytes promotes the phosphorylation and activation of the proapoptotic kinase Mst1. 27 Similarly, during pressure overload, K-Ras appeared to mediate Mst1 activation because phosphorylation of Mst1 was attenuated in Kras +/− , but not in Hras −/− , hearts after TAC ( Figure 5A and 5B). Interestingly, phosphorylation of AKT and ERK were not altered in Kras +/− hearts but were strikingly inhibited in Hras −/− heart samples. Examination of downstream signaling in cultured cardiomyocytes revealed that H-Ras12V expression engaged PI3K-AKT, leading to increased phosphorylation of AKT and glycogen synthase kinase (GSK)-3β (an established physiological substrate of active AKT), and increased AKT kinase activity, while the effect of K-Ras12V expression was less pronounced ( Figure  IVA and IVB in the Data Supplement). We also found that H-Ras knockdown (si-Hras) abolished phenylephrine-induced activation of AKT and ERK, yet si-Kras treatment had a less pronounced effect ( Figure 5C AKT has been implicated in cardiomyocyte hypertrophy and survival. [28] [29] [30] [31] Based on our mouse studies and cardiomyocyte results, we hypothesized that restoration of AKT activity might ameliorate the deleterious phenotype observed in Hras −/− mice after pressure overload. To test this hypothesis, we generated adeno-associated virus (AAV) to express exogenous AKT, or green fluorescent protein (GFP) as a control, and treated mice 2 weeks prior to TAC operation. Under basal conditions, LV mass, cardiomyocyte CSA, and %LVEF were modestly reduced in Hras −/− compared with those in WT mice ( Figure 6A through 6D and 6H ). Similar to the results shown in Figure 3 , we also observed attenuated hypertrophy, augmented fibrosis and apoptosis, and exacerbated cardiac dysfunction in Hras −/− mice after TAC when compared with WT ( Figure 6A through 6H and Table 3 ). TAC-induced fetal gene expression was attenuated in Hras −/− mice when compared with WT mice and was reversed to varying degrees by AKT-AAV, but not GFP-AAV ( Figure VII in the Data Supplement). Administration of AKT-AAV, but not GFP-AAV, significantly ameliorated the enhanced fibrosis, apoptosis, and cardiac dysfunction observed in Hras −/− mice ( Figure 6A through 6H and Table  3 ). Somewhat unexpectedly, we observed a modest attenuation of the hypertrophic response as determined by LV mass and cardiomyocyte CSA in Hras −/− mice supplemented with AKT-AAV after TAC (Figure 6B through 6D and Table 3 ). However, AKT normalization also significantly attenuated both TAC-induced lung congestion and increased wall stress in Hras −/− mice ( Figure VIII in the Data Supplement). We hypothesize that the reduction in stress achieved by AKT-AAV, and the diminished need for compensatory hypertrophy, may explain why LV mass and cardiomyocyte CSA were not normalized in AKT-AAV-treated Hras −/− mice. 
Discussion
Prior to this report, studies using a loss-of-function approach to investigate the role of Ras isoforms in mediating cardiac hypertrophy and dysfunction in response to hemodynamic stress were lacking. Using H-and K-Ras mutant mice, we observed a beneficial function of endogenous H-Ras that seems to promote hypertrophy and cardioprotection, whereas Kras +/− mice had an improved cardiac phenotype after TAC, suggesting that K-Ras contributes to dysfunction in response to chronic pressure overload. Our previous work demonstrated divergent outcomes downstream of H-and K-Ras during myocardial ischemia/reperfusion. In response to ischemia/reperfusion, Hras −/− mice had greater injury likely because of attenuated PI3K-AKT activation, while Kras +/− mice were protected because of inhibition of Mst1 and reduced mitochondriamediated cardiomyocyte apoptosis. 27 This study is consistent with those findings and implicates PI3K-AKT signaling as an important mechanism downstream of H-Ras that is needed for compensation in response to TAC-induced cardiac stress.
Mechanisms that mediate cardiac hypertrophy are complex and many. 32 For Ras proteins alone, there are several well-established downstream signaling pathways that have the potential to alter heart growth and function, including Raf-MEK-ERK, PI3K-AKT, and mitogen-activated protein kinase kinase kinase (MEKK) 1-c-Jun N-terminal kinase (JNK). Investigation into each of these cascades has provided a wealth of information; yet, the contribution of each to pathophysiology and disease remains somewhat unclear. Despite studies implicating a role for MEKK1-JNK in cardiomyocyte hypertrophy in vitro, 21 genetic deletion of MEKK1 in mice, the upstream kinase responsible for activating JNK, did not affect cardiac hypertrophy after pressure overload, suggesting that this pathway may not be critical for pathological heart growth. 33 Inhibition of Raf through cardiac expression of a dominant-negative mutant was shown to attenuate hypertrophy in response to pressure overload in mice, implicating this signaling pathway as a mediator of heart growth. 34 However, ERK1 −/− ERK2 +/− double mutant mice showed no change in hypertrophy after pressure overload. 35 Taken together, these results suggest that Raf signaling may diverge upstream of ERK to modulate the hypertrophic response. Forced expression of active PI3K (p110α) caused increased heart growth, whereas dominant-negative PI3K transgenic mice had smaller hearts at baseline and showed blunted hypertrophy after exercise but not pressure overload. 36, 37 Similarly, AKT transgenic mice had concentric hypertrophy and maintained systolic function, whereas Akt1 null mice were resistant to swimming-induced hypertrophy but showed exacerbated responses to pressure overload. [28] [29] [30] [31] These studies suggest that basal and physiological heart growth rely on PI3K-AKT signaling, whereas pathological hypertrophy elicited by hemodynamic stress may be mediated through alternate mechanisms.
Based on this background, we sought to determine the mechanism underlying H-Ras-mediated heart growth. Our results revealed a clear downregulation of AKT activation after TAC in hearts lacking H-Ras. Moreover, we used AAVmediated gene expression in vivo to show that restoration of AKT function was sufficient to ameliorate the detrimental effects of H-Ras deletion after pressure overload-specifically augmented fibrosis, apoptosis, and impaired cardiac function. Although we cannot rule out the contribution of additional signaling pathways downstream of H-Ras, these data indicate that AKT is an important target mediating a cardioprotective effect.
In addition to modulating cardiomyocyte growth and survival, AKT can also regulate angiogenesis and cardiomyocyte contractility, which may indirectly influence myocardial hypertrophy. Akt1 −/− mice showed reduced angiogenesis, as well as reduced endothelial nitric oxide synthase (eNOS) activation and nitric oxide production, after ischemia.
38 Akt1 null mice also had impaired vascular maturation, leading to leaky vessels, when compared with WT counterparts. 39 On the other hand, mice engineered to express AKT in cardiomyocytes, 40 or selectively in endothelial cells in an inducible manner, 41 had increases in angiogenesis, capillary density, NO production, and heart function after pressure overload, while endothelial cell apoptosis was attenuated. These findings demonstrate that enhanced vascular AKT activity can promote vessel formation, maturation, and protection against insult, indicating its importance for adaptation to pathological stress.
AKT also modulates calcium handling and contractility of cardiomyocytes. Gain of function AKT transgenic mice had significantly increased contractility, concomitant with increases in SERCA expression, SR Ca 2+ load, and phosphorylation of phospholamban (PLN). 28, 42, 43 Adenoviral AKT transduction of rat hearts showed similar results. 44 However, prolonged expression of AKT elicited cardiac dysfunction, which was attributed to insufficient coupling of angiogenesis, indicating that the duration of AKT activation as well as myocyte/vessel growth are critical determinants of heart function. 45 Although the heart typically responds to increased demand via enlargement, it is plausible that AAV-AKT administration may increase cardiac contractility or angiogenesis independent of growth and could explain why we observed attenuated hypertrophy in Hras −/− +AAV-AKT mice but improved cardiac function.
We have shown previously that H-and K-Ras isoforms can have divergent signaling and outcomes in cardiomyocytes. 27 Our prior findings, and current data, point to differences in subcellular localization of Ras isoforms that may be responsible for different effects of each in cardiomyocytes. In other cell types, Ras isoforms have been shown to localize to different cellular compartments, which can modulate association with downstream effectors and altered 46-49 Interestingly, differences in posttranslational modification and intracellular processing of H-and K-Ras are established and can affect protein trafficking, localization, and signaling. 1 Although less is known in cardiomyocytes, this is one possible explanation for the disparities observed between these 2 isoforms and warrants further exploration.
Interestingly, previous work demonstrated that levels of H-Ras expression correlated with cardiomyocyte size in patients with hypertrophic cardiomyopathy. 50 It has also been shown that the developmental disorders termed RASopathies, which are caused by dysfunctional Ras signaling, share phenotypic overlap, including cardiovascular defects such as hypertrophic cardiomyopathy among others. These findings suggest that H-Ras may be an important modulator of cardiac growth in human disease. Furthermore, our data demonstrate that H-Ras activation is increased by acute pressure overload (1 day) but not by 7 days post-TAC in the murine heart, whereas K-Ras activation seems to be maintained. Because endogenous H-Ras seems to counteract the progression to heart failure, it may be of interest to determine whether maintenance of physiological H-Ras activity could prove beneficial in the face of hemodynamic stress. On the other hand, because K-Ras disruption afforded cardioprotection, perhaps selective inhibition of this isoform could improve outcomes during hypertension.
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CLINICAL PERSPECTIVE
Ras proteins are small GTPases that regulate numerous functions within the cell. Mutations in Ras proteins and Ras-related signaling genes are linked to several disorders collectively known as RASopathies that can present with cardiac abnormalities; yet, the underlying molecular mechanisms remain largely unclear. In cardiomyocytes, Ras proteins are thought to mediate hypertrophy in response to agonist stimulation through activation of downstream signaling pathways and altered gene expression. However, in vivo, the role of Ras proteins in response to hypertrophic stress, and whether selective Ras isoforms have redundant functions, was not known. In this study, we used H-and K-Ras knockout mice to determine the role of endogenous Ras isoforms in mediating cardiac hypertrophy and progressive dysfunction in response to chronic pressure overload stress. Our findings indicate that mice lacking H-Ras have attenuated hypertrophy and worsened heart function after stress, whereas K-Ras deficiency did not alter cardiac hypertrophy but improved function after pressure overload. H-Ras null hearts had downregulation of AKT, a kinase known to mediate cardiomyocyte survival and hypertrophy. Treatment of H-Ras knockout mice with adeno-associated virus to restore AKT expression was able to ameliorate the stress-induced cardiac dysfunction, indicating involvement of AKT signaling. These results suggest that H-and K-Ras isoforms have distinct functions in the heart, and selective targeting should be considered for potential therapeutic interventions.
